Department of Orthopedics and Physical Rehabilitation
Amino Acids, Peptides, and Proteins | Immune System Diseases | Musculoskeletal Diseases | Pharmaceutical Preparations | Rheumatology | Skin and Connective Tissue Diseases | Therapeutics
The objective of the study was to examine whether disease duration independently predicts treatment response among biologic-naive patients with rheumatoid arthritis (RA) initiating abatacept in clinical practice. Using the Corrona RA registry (February 2006-January 2015), biologic-naive patients with RA initiating abatacept with 12-month (+/-3 months) follow-up and assessment of disease activity (Clinical Disease Activity Index [CDAI]) at initiation and at 12 months were identified. The primary outcome was mean change in CDAI (DeltaCDAI) from baseline to 12 months. Secondary outcomes at 12 months included achievement of low disease activity (LDA; CDAI 10 years, n = 79). Increased disease duration was associated with older age (p = 0.047), and the median number of prior conventional disease-modifying antirheumatic drugs used was lowest in the 0- to 2-year duration group (p < 0.001). Mean DeltaCDAI (SE) ranged from -10.22 (1.19) for 0-2 years to -4.63 (1.38) for > 10 years. In adjusted analyses, shorter disease duration was significantly associated with greater mean DeltaCDAI (p = 0.015) and greater likelihood of achieving LDA (p = 0.048). In biologic-naive patients with RA initiating abatacept, earlier disease (shorter disease duration) was associated with greater DeltaCDAI and likelihood of achieving LDA.
Disease activity, Disease-modifying antirheumatic drugs (DMARDs), Non-TNFi biologic, Outcome measures, Registry, Rheumatoid arthritis
Rights and Permissions
© The Author(s) 2017. This article is published with open access at Springerlink.com.
DOI of Published Version
Clin Rheumatol. 2017 Mar 1. doi: 10.1007/s10067-017-3588-7. Link to article on publisher's site
Harrold LR, Litman HJ, Connolly SE, Kelly S, Hua W, Alemao E, Rosenblatt L, Rebello S, Kremer JM. (2017). A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice. University of Massachusetts Medical School Faculty Publications. https://doi.org/10.1007/s10067-017-3588-7. Retrieved from https://escholarship.umassmed.edu/faculty_pubs/1199
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Amino Acids, Peptides, and Proteins Commons, Immune System Diseases Commons, Musculoskeletal Diseases Commons, Pharmaceutical Preparations Commons, Rheumatology Commons, Skin and Connective Tissue Diseases Commons, Therapeutics Commons